Upper Gastrointestinal Surgery, Guy's and St Thomas' NHS Foundation Trust, London, England2Section of Gastrointestinal Cancer, Division of Cancer Studies, King's College London, London, England3Upper Gastrointestinal Surgery, Department of Molecular Medic.
Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
JAMA Surg. 2016 Jan;151(1):32-9. doi: 10.1001/jamasurg.2015.2611.
The prognostic role of the extent of lymphadenectomy during surgery for esophageal cancer is uncertain and requires clarification.
To clarify whether the number of removed lymph nodes influences mortality following surgery for esophageal cancer.
DESIGN, SETTING, AND PARTICIPANTS: Conducted from January 1, 2000, to January 31, 2014, this was a cohort study of patients who underwent esophagectomy for cancer in 2000-2012 at a high-volume hospital for esophageal cancer surgery, with follow-up until 2014.
The main exposure was the number of resected lymph nodes. Secondary exposures were the number of metastatic lymph nodes and positive to negative lymph node ratio.
The independent role of the extent of lymphadenectomy in relation to all-cause and disease-specific 5-year mortality was analyzed using Cox proportional hazard regression models, providing hazard ratios (HRs) with 95% CIs. The HRs were adjusted for age, pathological T category, tumor differentiation, margin status, calendar period of surgery, and response to preoperative chemotherapy.
Among 606 included patients, 506 (83.5%) had adenocarcinoma of the esophagus, 323 (53%) died within 5 years of surgery, and 235 (39%) died of tumor recurrence. The extent of lymphadenectomy was not statistically significantly associated with all-cause or disease-specific mortality, independent of the categorization of lymphadenectomy or stratification for T category, calendar period, or chemotherapy. Patients in the fourth quartile of the number of removed nodes (21-52 nodes) did not demonstrate a statistically significant reduction in all-cause 5-year mortality compared with those in the lowest quartile (0-10 nodes) (HR, 0.86; 95% CI, 0.63-1.17), particularly not in the most recent calendar period (HR, 0.98; 95% CI, 0.57-1.66 for years 2007-2012). A greater number of metastatic nodes and a higher positive to negative node ratio was associated with increased mortality rates, and these associations showed dose-response associations.
This study indicated that the extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival. These results challenge current clinical guidelines.
在食管癌手术中淋巴结清扫范围的预后作用尚不确定,需要进一步阐明。
阐明食管癌手术后切除的淋巴结数量是否会影响死亡率。
设计、设置和参与者:这是一项队列研究,纳入了 2000 年至 2012 年在一家高容量食管癌手术医院接受食管癌切除术的患者,随访至 2014 年。从 2000 年 1 月 1 日至 2014 年 1 月 31 日进行研究。
主要暴露因素为切除的淋巴结数量。次要暴露因素为转移性淋巴结数量和阳性与阴性淋巴结比值。
使用 Cox 比例风险回归模型分析淋巴结清扫范围与全因和疾病特异性 5 年死亡率的独立作用,提供具有 95%置信区间的风险比(HR)。HR 通过年龄、病理 T 分期、肿瘤分化、切缘状态、手术时间和术前化疗反应进行调整。
在 606 例纳入患者中,506 例(83.5%)患有食管腺癌,323 例(53%)在手术后 5 年内死亡,235 例(39%)死于肿瘤复发。淋巴结清扫范围与全因或疾病特异性死亡率无统计学显著相关性,与淋巴结清扫范围的分类或 T 分期、时间、或化疗无关。在第四四分位数(21-52 个淋巴结)中移除的淋巴结数量的患者与最低四分位数(0-10 个淋巴结)相比,全因 5 年死亡率无统计学显著降低(HR,0.86;95%CI,0.63-1.17),特别是在最近的时间(HR,0.98;95%CI,2007-2012 年为 0.57-1.66)。更多的转移性淋巴结和更高的阳性与阴性淋巴结比值与死亡率升高相关,这些关联呈剂量反应关系。
本研究表明,食管癌手术中淋巴结清扫的范围可能不会影响 5 年全因或疾病特异性生存率。这些结果对当前的临床指南提出了挑战。